Results 231 to 240 of about 74,884 (346)

d‐amino acids: new functional insights

open access: yesThe FEBS Journal, EarlyView.
This review explores recent advances in understanding d‐amino acids (d‐AAs) and their pivotal roles across organisms, from plants to humans. d‐AAs have been implicated in key physiological processes, including cancer, inflammation, immune regulation, kidney disease, diabetes, and nervous system function.
Loredano Pollegioni   +5 more
wiley   +1 more source

Linkage of Infantile Bartter Syndrome with Sensorineural Deafness to Chromosome 1p [PDF]

open access: bronze, 1998
Theresa Brennan   +8 more
openalex   +1 more source

Examining the association between placental malperfusion assessed by histopathological examination and child and adolescent neurodevelopment: a systematic review

open access: yesJournal of Child Psychology and Psychiatry, EarlyView.
Background Placental malperfusion, categorised into maternal vascular malperfusion (MVM) and foetal vascular malperfusion (FVM), is a main placental pathology known to affect placental functioning and offspring outcomes. The aim of this review is to evaluate the association between exposure to placental malperfusion and offspring neurodevelopment from ...
Noha Ibrahim   +6 more
wiley   +1 more source

Audiological Features in Patients with Rheumatoid Arthritis: A Systematic Review. [PDF]

open access: yesInt J Mol Sci
Chen JJ   +5 more
europepmc   +1 more source

Sudden Low-tone Sensorineural Deafness

open access: bronze, 1990
Eiko Tanaka   +4 more
openalex   +2 more sources

A New Mouse Insertional Mutation That Causes Sensorineural Deafness and Vestibular Defects [PDF]

open access: bronze, 1999
Kumar N. Alagramam   +6 more
openalex   +1 more source

Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
ALLEGRO‐LT (NCT04006457) is an open‐label, phase 3 study investigating the long‐term safety and efficacy of ritlecitinib in patients with alopecia areata (AA). In this analysis in 449 de novo patients with AA and ≥25% scalp hair loss, ritlecitinib demonstrated clinical efficacy and had an acceptable safety profile through Month 24.
C. Tziotzios   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy